Fig. 3
Knockdown of Nogo-B inhibits NASH and HCC progression. a Scheme of HFHC-promoted NASH-associated HCC model. b, c Representative (b) western blot images and (c) quantification of Nogo-B expression in the livers of DEN-treated and, LFD- or HFHC-fed mice administered with lentivirus expressing shCtrl or shNogo-B. Mice were sacrificed at 28 weeks of age. LFD/shCtrl: n = 6, HFHC/shCtrl: n = 14, HFHC/shNogo-B: n = 16. d Representative liver pictures (top), H&E staining (middle) and Nile red staining (bottom) in the livers of LFD- and HFHC-fed mice with lentivirus administration. e The average tumor multiplicity of LFD- and HFHC-fed mice described in c. f The percentages of positively stained Nile red areas in the livers of LFD- and HFHC-fed mice described in c. g Blood glucose of 26-week-old HFHC-fed mice at indicated time-points after glucose injection in IPGTT analysis (n = 12 in each group). h, i Serum h FFA and i TG concentrations of LFD- and HFHC-fed mice described in c. (*p < 0.05, **p < 0.01, ****p < 0.0001. Source data are provided as a Source Data file)
